Novasep opens new 2,000 m2 expanded Shanghai facilities to meet increasing East Asia demand
New site increases Novasep’s process development and engineering capabilities to supply turnkey purification processes in East Asia
Novasep announced the opening of a new 2,000 m2 facility in Shanghai Pudong district, China. The site will boost Novasep's process development and engineering capabilities to cater for ever-increasing Chinese and East Asian demand. These facilities will also add to Novasep’s existing 12 global synthesis and process sites in France, US, Germany, Belgium and The Bahamas.
Novasep launched its previous facilities in Shanghai in 2006, and quickly outgrew the site whilst the company doubled its staff to almost 50 employees between 2010 and 2012. The new 2,000 m2 expanded facilities includes 800 m2 dedicated to innovation and process development through new laboratory, piloting and FAT testing areas.
“Novasep, as the leader in the supply of purification processes for industrial biotech and biopharmaceutical applications in China, has ensured that its supply capabilities can satisfy ever increasing demands in China and East Asia,” said Antoine Baule, president of Novasep Process, the biomolecule division of Novasep.
“With food and feed industry ingredient volumes rising above 100,000 tons per year in some Chinese productions, this requires more cost effective and environmentally friendly processes, and strong engineering capabilities,” said Jean de Lataillade, general manager of Novasep Asia. “The Shanghai site will further enable Novasep to compete globally in both low volume pharma markets, as well as large volume industrial biotech markets.”
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Merck to Develop Abituzumab in Metastatic Colorectal Cancer with SFJ Pharmaceuticals Group

Scientists identify enzymes that create a highly toxic form of mercury in Antarctic sea ice

CO2 for a clean performance: Rheticus research project by Evonik and Siemens enters phase 2 - High-value specialty chemicals produced from CO2 and water using electricity from renewable sources and bacteria
Roche Joins in Spanish Research Cooperation for Personalized Treatment of Hepatitis B and C

Neuroscientists illuminate how brain cells deep in the cortex operate in freely moving mice - This new miniature microscope is a game changer for exploring the link between neural activity and complex animal behavior
Scientists create compounds that dramatically alter biological clock and lead to weight loss - The new molecules could lead to unique treatments for obesity, diabetes, high cholesterol, and sleep disorders
QIAGEN and Bio*One Capital Enter into Joint Venture to Develop Molecular Diagnostics Products - Assay development centre for Singapore will support QIAGEN in the market for molecular testing solutions
Researchers Identify Genetic Mutation That May Alter Patients' Response to Cancer Therapeutics - Recurring mutation found in breast, colorectal and ovarian cancers
OctoPlus wins drug development and manufacturing contract from Danish pharmaceutical company
